MedTideUSA is building toward clinician-guided, pharmacy-compliant access to a defined portfolio of peptide therapies. We are not prescribing or dispensing today. Availability will depend on FDA and state requirements, clinician review, and safety protocols.
Join the waitlist for portfolio updates, eligibility guidance, and notification when compliant access becomes available.
MedTideUSA is building toward clinician-guided, pharmacy-compliant access to selective peptide therapies. Availability, indication, and timing remain subject to FDA and state requirements, clinician review, and safety protocols. We do not sell or prescribe peptides today.
First release window
End of July 2026
Our initial portfolio focuses on peptides most often discussed in recovery, metabolic, and neurologic research — each subject to applicable law, clinician review, and pharmacy compliance before any access is offered.
Second release window
February 2027
A follow-on set of peptide therapies we are preparing to support through the same compliant access standards, pending regulatory clarity and clinical eligibility review.
Join the waitlist to receive portfolio updates, regulatory context, and notification when eligible access pathways become available in your state.
Join the waitlistMedTideUSA is being built for patients and clinicians who want a serious, compliant pathway to peptide therapies — with education, regulatory context, and operational readiness before any access is offered.
Future pathways are being designed around licensed clinician evaluation, eligibility review, and follow-up — not self-directed use.
We publish plain-English education on what research suggests, what remains uncertain, and how regulatory requirements may affect availability.
Our planned peptide portfolio is organized in release windows so patients and clinicians can understand what may become available over time.
We are building toward sourcing and fulfillment models that align with applicable federal and state requirements as they evolve.
MedTideUSA is preparing the clinical, educational, and operational foundation required before any peptide therapy access is offered in the United States.
Define the peptide therapies we are preparing to support, align on clinician review standards, and publish education on each therapy in plain language.
Track FDA, compounding, and state requirements so future access can be offered only through lawful, auditable channels.
Subject to applicable law and clinician review, connect waitlist members to compliant access options as each therapy becomes available.
Guides focused on the peptide therapies in our planned portfolio and the clinical questions patients and clinicians are asking today.
A research-focused overview of one of the first peptides in our planned access portfolio, including what is known, what is uncertain, and how U.S. rules may affect availability.
How recovery-related peptides are discussed in research and what clinicians may consider when evaluating future access pathways.
A plain-English primer on peptide therapies, how they differ from proteins and hormones, and how they are studied.
Context on metabolic and weight-related peptide research, including how approved therapies differ from investigational compounds.
After our planned portfolio, we publish U.S. legal context so patients and clinicians can understand how access requirements may affect each therapy over time.
How federal rules may affect which peptide therapies can be compounded, prescribed, and dispensed in the United States.
Read moreWhy compounding has been central to peptide access discussions and what may change as FDA policy evolves.
Read moreA careful overview of how legality depends on the specific therapy, the care pathway, and current federal and state rules.
Read moreJoin the MedTideUSA waitlist for portfolio updates, regulatory context, and early notification when compliant peptide access becomes available.
MedTideUSA is currently informational only. Future services, if available, will be subject to applicable law, clinician review, and safety protocols.